Related references
Note: Only part of the references are listed.What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea
Hyeri Seok et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-Resistant Infections-A Systematic Review and Meta-analysis
Samir Samal et al.
INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2021)
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
Amir Nutman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
Wasan Katip et al.
ANTIBIOTICS-BASEL (2020)
Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii: A Prospective Cohort Study
Wasan Katip et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2019)
Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
So Yeon Park et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)
Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis
Adrian Schmid et al.
SCIENTIFIC REPORTS (2019)
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial
Yaakov Dickstein et al.
CLINICAL INFECTIOUS DISEASES (2019)
Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis
Jin Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
HyeJin Shi et al.
INFECTION AND DRUG RESISTANCE (2019)
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis
Kirati Kengkla et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals
L. Papst et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials
I-Ling Cheng et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
Sombat Leelasupasri et al.
JOURNAL OF PATHOGENS (2018)
Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
Oren Zusman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
J. Nowak et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance
Yee-Huang Ku et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A-baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques
Micheline A. H. Soudeiha et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients
Wasan Katip et al.
INFECTION AND DRUG RESISTANCE (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Colistin
Nicolas Gregoire et al.
CLINICAL PHARMACOKINETICS (2017)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
Maria Helena Rigatto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia
Gul Ruhsar Yilmaz et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2015)
Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection
Zhijin Chen et al.
SCIENTIFIC REPORTS (2015)
Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
A. Batirel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort
L. E. Lopez-Cortes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy
Robbert Crusio et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2014)
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Oren Zusman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management
Jason M. Pogue et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Pranita D. Tamma et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?
F. Simsek et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2012)
Multiresistant Acinetobacter baumannii infections: epidemiology and management
Jose Garnacho-Montero et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2010)
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
Matthew E. Falagas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
N. Petrosillo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Systems for grading the quality of evidence and the strength of recommendations -: I:: Critical appraisal of existing approaches The GRADE Working Group -: art. no. 38
D Atkins et al.
BMC HEALTH SERVICES RESEARCH (2004)
Share Paper
